Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations''), we hereby inform ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Gujarat Inject Kerala Limited, at its meeting on 14 February 2026, approved the unaudited standalone financial results for Q3 FY26 and the nine months ended 31 December 2025. Revenue from operations for the quarter fell sharply to ₹162.51 lakh from ₹502.26 lakh in Q3 FY25, a year-on-year drop of roughly 68%. For the nine-month period, revenue declined to ₹1,490.46 lakh from ₹1,977.11 lakh in the prior year period. Profit after tax for the quarter came in at just ₹3.80 lakh versus ₹21.16 lakh a year ago, while 9M PAT slipped to ₹94.40 lakh from ₹101.72 lakh. Statutory auditor S. Mandawat & Co. issued a clean limited review report with no qualifications or matters of emphasis.
Sharp revenue compression in Q3 with margins under pressure signals weak near-term operating performance; while PAT remains positive, the steep YoY decline in quarterly earnings is a negative signal for short-term shareholder sentiment.